At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
SCY-078drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris
In Brief
A Phase 3 clinical trial evaluating SCY-078 for Candidiasis, Invasive and Candidemia. Completed, enrolled 30 participants across 12 sites in 4 countries.
Detailed Summary
This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCandidiasis, Invasive, Candidemia
CountriesIndia, Pakistan, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionApr 2023
Study CompletionMay 2023
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartNov 15, 2017
Primary CompletionApr 14, 2023
Study CompletionMay 24, 2023
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.6 years ago
Interventions
SCY-078drug
Oral SCY-078